Underestimating regulatory change risks, page-44

No insinuation at all, just a statement of fact. The following is extracted from Note 2 to the accounts:

		FY19	1H20
1		A$m	A$m
2	Group Revenue	264.1	220.3
3
4	Segmental EBITDA	63.8	27.9
5	Corporate Costs	35.1	21.2
6	EBITDA (exc significant items)	28.7	6.7
7
8	ANZ Revenue	196.8	135.2
9	ANZ Segmental EBITDA	87.0	63.6
10	Corporate Costs Allocation*	26.2	13.0
11	ANZ EBITDA (exc signif items)	60.8	50.6
12	ANZ EBITDA Margin	30.9%	37.4%
13
14	US Revenue	39.0	56.6
15	US Segmental EBITDA	-24.6	-30.7
16	Corporate Costs Allocation*	5.2	5.4
17	US EBITDA (exc signif items)	-29.8	-36.1
18	US EBITDA Margin
19
20	ROW Revenue	11.2	20.4
21	ROW Segmental EBITDA	-3.5	-7.7
22	Corporate Costs Allocation*	1.5	2.0
23	ROW EBITDA (exc signif items)	-5.0	-9.7
24	ANZ EBITDA Margin
25
26	Pay Now Revenue	17.1	8.1
27	Pay Now Segmental EBITDA	4.9	2.7
28	Corporate Costs Allocation*	2.3	0.8
29	Pay Now EBITDA (exc signif items)	2.6	1.9
30	Pay Now EBITDA Margin	15.4%	23.7%

* Corporate Costs allocated in the same ratio as contribution to Group Revenue

As you can see, in 1H20 ANZ EBITDA (before significant items and share based payments) was $50.6m. My expectation is it will be ~$110m for the full year.